Clinical trial readout dates for ACADIA Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is August 2027.
| Phase 2 ACP-211 Major Depressive Disorder (MDD); Depressive Disorder, Treatment-Resistant · NCT07284667 | August 2027 Recruiting |
| Phase 2/3 ACP-204 Alzheimer's Disease Psychosis · NCT06159673 | January 2028 Recruiting |
| Phase 2 ACP-204 Lewy Body Dementia Psychosis · NCT07029581 | February 2028 Recruiting |
| Phase 3 ACP-204 Lewy Body Dementia Psychosis · NCT07095465 | February 2029 Recruiting |
| Phase 3 ACP-204 Alzheimer's Disease Psychosis · NCT06194799 | April 2029 Enrolling |
ACADIA Pharmaceuticals Inc. reported $976M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). It reported net income of $54M for that quarter.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-04 |